Vir/GSK Move Lead Coronavirus Antibody Into Phase III
Safety In 20 Phase II Patients Enabled Testing In 1,300 People
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
You may also be interested in...
A CDC recommendation slowed non-pandemic vaccinations, but Shingrix shots will likely increase as more eligible consumers are fully vaccinated against SARS-CoV-2.
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.